Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) received a $14.00 price target from investment analysts at Canaccord Genuity in a note issued to investors on Friday. The brokerage presently has a “hold” rating on the specialty pharmaceutical company’s stock. Canaccord Genuity’s target price indicates a potential downside of 7.47% from the stock’s previous close.

A number of other equities research analysts have also weighed in on the stock. Stifel Nicolaus restated a “buy” rating and issued a $35.00 price objective (down from $45.00) on shares of Valeant Pharmaceuticals International in a report on Wednesday, May 17th. Deutsche Bank AG lowered their price objective on shares of Valeant Pharmaceuticals International from $19.00 to $18.00 and set a “hold” rating for the company in a report on Wednesday, April 19th. Piper Jaffray Companies restated an “outperform” rating and issued a $10.00 price objective on shares of Valeant Pharmaceuticals International in a report on Friday, April 14th. Scotiabank boosted their price objective on shares of Valeant Pharmaceuticals International from $12.00 to $14.00 and gave the stock a “sector perform” rating in a report on Wednesday, May 10th. Finally, J P Morgan Chase & Co restated a “hold” rating on shares of Valeant Pharmaceuticals International in a report on Tuesday, May 9th. Four investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Valeant Pharmaceuticals International presently has a consensus rating of “Hold” and an average price target of $16.96.

Shares of Valeant Pharmaceuticals International (NYSE VRX) traded down 2.07% during trading on Friday, reaching $15.13. 18,721,769 shares of the company’s stock traded hands. The company’s market cap is $5.26 billion. Valeant Pharmaceuticals International has a 52-week low of $8.31 and a 52-week high of $32.74. The company’s 50-day moving average is $16.16 and its 200 day moving average is $13.34. Valeant Pharmaceuticals International also was the recipient of unusually large options trading activity on Thursday. Investors acquired 16,974 put options on the company. This represents an increase of 100% compared to the typical volume of 8,473 put options.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.87 by $1.93. The firm had revenue of $2.11 billion during the quarter, compared to analyst estimates of $2.17 billion. Valeant Pharmaceuticals International had a negative net margin of 14.96% and a positive return on equity of 58.02%. The business’s quarterly revenue was down 11.1% on a year-over-year basis. During the same period in the previous year, the business posted ($1.08) EPS. Equities analysts forecast that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Valeant Pharmaceuticals International, Inc. (NYSE:VRX) PT Set at $14.00 by Canaccord Genuity” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/06/valeant-pharmaceuticals-international-inc-nysevrx-pt-set-at-14-00-by-canaccord-genuity.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De bought 20,000 shares of Valeant Pharmaceuticals International stock in a transaction dated Thursday, May 11th. The shares were purchased at an average cost of $13.90 per share, with a total value of $278,000.00. Following the transaction, the director now directly owns 70,572 shares of the company’s stock, valued at $980,950.80. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 5.87% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in VRX. Gruss & Co. Inc. acquired a new stake in Valeant Pharmaceuticals International during the first quarter worth $104,000. Financial Architects Inc increased its stake in Valeant Pharmaceuticals International by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 1,500 shares in the last quarter. Harbor Advisors LLC acquired a new stake in Valeant Pharmaceuticals International during the first quarter worth $110,000. NEXT Financial Group Inc increased its stake in Valeant Pharmaceuticals International by 6.2% in the second quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock worth $178,000 after buying an additional 600 shares in the last quarter. Finally, WMS Partners LLC acquired a new stake in Valeant Pharmaceuticals International during the first quarter worth $116,000. 50.53% of the stock is currently owned by hedge funds and other institutional investors.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.